İçeriğe atla
Stories
CN
Developing

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Started 16 Nov, 05:00 1 events Updated 1d ago
Paylaş
Bağlam · AI üretimi

Bağlam, hikayenin etrafındaki ülke + lider + komşu hikaye ağına dayanılarak AI tarafından üretildi. Olgu içerikleri için her zaman üstteki kaynak linklerine başvurun.

Bu gündemi takip et

Çin gelişmelerini kaçırma — ücretsiz kaydol, günlük brifinginde gör.

React to this story:

Timeline

latest: 1d ago
  1. Humanitarian16 Nov, 05:00

    Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

    Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global...

ilgili gelişmeler